Unilever invests in advanced woundcare co:
This article was originally published in Clinica
Georgia, Atlanta-based woundcare specialist Biofisica has closed a $5m series A financing round, led by Unilver Technology Ventures. Other participants in the round include Novartis Venture Fund, Advanced Technology Development Seed Capital Fund and existing investors. The funding will go towards the planned UK launch of Biofisica's POSiFECT RD bioelectric stimulation therapy, as well as to initial regulatory filings for US regulatory clearance, expansion of the company's workforce on both sides of the Atlantic and development of the product portfolio. The POSiFECT RD, CE-marked in October (see Clinica No 1230, p 18), is a moist woundcare dressing with electrical stimulation properties to manage difficult-to-heal or non-healing chronic wounds.
You may also be interested in...
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.